skip to Main Content

KRAS Pathway Expression Changes in Pancreatic Cancer Models by Conventional and Txperimental Taxanes

KRAS Pathway Expression Changes in Pancreatic Cancer Models by Conventional and Txperimental Taxanes
The KRAS signalling pathway is pivotal for pancreatic ductal adenocarcinoma (PDAC) development. After the failure of most conventional cytotoxic and targeted therapeutics tested so far, the combination of taxane nab-paclitaxel (Abraxane) with gemcitabine recently demonstrated promising improvements in the survival of PDAC patients. This study aimed to explore interactions of conventional paclitaxel and experimental taxane SB-T-1216 with the KRAS signalling pathway expression in in vivo and in vitro PDAC models in order to decipher potential predictive biomarkers or targets for future individualised therapy.

Read more . . . 


Back To Top